COSMOS Pharmaceutical Corporation
3349.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | ¥272 | ¥259 | ¥246 | ¥244 |
| % Growth | 5.1% | 5.2% | 0.9% | – |
| Cost of Goods Sold | ¥215 | ¥205 | ¥193 | ¥193 |
| Gross Profit | ¥57 | ¥54 | ¥53 | ¥52 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥46 | ¥25 | ¥42 | ¥43 |
| Sales & Mktg Exp. | ¥0 | ¥2 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥21 | ¥0 | ¥0 |
| Operating Expenses | ¥46 | ¥45 | ¥42 | ¥43 |
| Operating Income | ¥12 | ¥9 | ¥11 | ¥9 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | ¥0 | ¥0 | ¥0 | ¥1 |
| Pre-Tax Income | ¥12 | ¥9 | ¥12 | ¥9 |
| Tax Expense | ¥4 | ¥1 | ¥4 | ¥3 |
| Net Income | ¥8 | ¥9 | ¥8 | ¥6 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 103.09 | 108.95 | 99.86 | 79.3 |
| % Growth | -5.4% | 9.1% | 25.9% | – |
| EPS Diluted | 103.09 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥6 | ¥6 | ¥6 | ¥5 |
| EBITDA | ¥18 | ¥15 | ¥17 | ¥14 |
| % Margin | 6.6% | 5.9% | 7.1% | 5.8% |